Thomas Yuen-tung Lam

Dr. Thomas Yuen-tung Lam

The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
MCMax F K Cheung
Max F K Cheung
YMYasmin L Munro
Yasmin L Munro
KLKong Meng Lim
Kong Meng Lim
DSDennis Shung
Dennis Shung
JSJoseph JY Sung
Joseph JY Sung
Background: The number of artificial intelligence (AI) studies in medicine has exponentially increased recently. However, there is no clear quantification of the clinical benefits of implementing AI-assisted tools in patient care. Objective: This study aims to systematically review all published randomized controlled trials (RCTs) of AI-assisted tools to characterize their performance in clinical practice. Methods: CINAHL, Cochrane Central, Embase, MEDLINE, and PubMed were searched to identify relevant RCTs published up to July 2021 and comparing the performance of AI-assisted tools with conventional clinical management without AI assistance. We evaluated the primary end points of each study to determine their clinical relevance. This systematic review was conducted following the updated PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Results: Among the 11,839 articles retrieved, only 39 (0.33%) RCTs were included. These RCTs were conducted in an approximately equal distribution from North America, Europe, and Asia. AI-assisted tools were implemented in 13 different clinical specialties. Most RCTs were published in the field of gastroenterology, with 15 studies on AI-assisted endoscopy. Most RCTs studied biosignal-based AI-assisted tools, and a minority of RCTs studied AI-assisted tools drawn from clinical data. In 77% (30/39) of the RCTs, AI-assisted interventions outperformed usual clinical care, and clinically relevant outcomes improved with AI-assisted intervention in 70% (21/30) of the studies. Small sample size and single-center design limited the generalizability of these studies. Conclusions: There is growing evidence supporting the implementation of AI-assisted tools in daily clinical practice; however, the number of available RCTs is limited and heterogeneous. More RCTs of AI-assisted tools integrated into clinical practice are needed to advance the role of AI in medicine. Trial Registration: PROSPERO CRD42021286539; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=286539

16 August 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
AHAric J Hui
Aric J Hui
FSFelix Sia
Felix Sia
MWMei Y Wong
Mei Y Wong
CLCasper C P Lee
Casper C P Lee
JSJoseph J Y Sung
Joseph J Y Sung

7 December 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Rashid Nok Shun LuiRashid Nok Shun Lui
Rashid Nok Shun Lui
MKMoe H. Kyaw
Moe H. Kyaw
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
JCJessica Y.L. Ching
Jessica Y.L. Ching
VCVictor C.W. Chan
Victor C.W. Chan
JSJoseph JY Sung
Joseph JY Sung

20 November 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
PWPeter I. Wu
Peter I. Wu
RTRaymond S. Y. Tang
Raymond S. Y. Tang
ALArthur K. C. Luk
Arthur K. C. Luk
SNSimpson Ng
Simpson Ng
JSJoseph JY Sung
Joseph JY Sung

7 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZZZiyue Zhu
Ziyue Zhu
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
RTRaymond Shing Yan Tang
Raymond Shing Yan Tang
SWSunny Hei Wong
Sunny Hei Wong
RLRashid Nok Shun Lui
Rashid Nok Shun Lui
JSJoseph Jao Yiu Sung
Joseph Jao Yiu Sung
Hypothesis: The objective of this study is to evaluate the predictive ability of the TyG index for the presence of adenoma and multiple adenomas in an asymptomatic population. Design: A secondary analysis was conducted on a prospective cohort of asymptomatic subjects aged between 50 and 75 who underwent CRC screening. Fasting blood glucose (FBG) and lipid profiles were measured within three months prior colonoscopy. TyG index was estimated as ln [fasting triglycerides (mg/dL) × FBG (mg/dL)/2]. Multivariate logistic regression was performed to assess the association between the TyG index and the risk of adenoma. Its association with multiple adenomas (≥5) and the continuous number of adenomas were assessed by multinomial regression and log-normal linear regression, respectively. Results: A total of 1,538 subjects were recruited among which 876 subjects (57%) had at least one adenoma detected. Elevated TyG index was positively associated with the incidence of adenoma (adjusted odds ratio [aOR]: 1.26, 95% confidence interval [CI]: 1.04–1.54). Compared with the lowest TyG index (≤ 8) group, the risk of adenoma was the highest among subjects in the highest TyG index (> 10) group (aOR: 3.36, 95% CI: 1.44–7.73). As compared to the non-adenoma group, the TyG index was also positively associated with multiple adenomas (aOR: 1.74, 95% CI: 1.17–2.57), and the estimate was also the highest in the highest TyG group (aOR: 14.49, 95% CI: 3.12–67.20). As for the number of adenomas, the positive association was maintained (Estimates: 1.06, 95% CI: 1.01–1.12) while the number of adenomas increase the most in the highest TyG index group (Estimates: 1.35, 95% CI: 1.10–1.65). Conclusions: Elevated TyG index is associated with an increased risk of colorectal adenoma and an increased number of adenomas for asymptomatic subjects aged ≥50. Trial registration: This study was registered on clinicaltrials.gov (NCT03597204 and NCT04034953).

26 September 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Martin WongMartin Wong
Martin Wong
Junjie HuangJunjie Huang
Junjie Huang
Thomas Yuen-tung LamThomas Yuen-tung Lam
Thomas Yuen-tung Lam
LLLouis Hs Lau
Louis Hs Lau
PCPhilip Wai Yan Chiu
Philip Wai Yan Chiu
Background: Colorectal cancer (CRC) is the third most common cancer worldwide and poses a heavy burden on health care systems. Early screening for CRC through colonoscopy can effectively reduce both the incidence and mortality associated with CRC. However, the sensitivity of conventional colonoscopy is limited by the level of experience of physicians. Recently, artificial intelligence (AI)–assisted colonoscopy has been shown to have higher sensitivity in detecting CRC and mitigating the limitations concerning physician experience, but few studies have evaluated the cost-effectiveness of AI-assisted colonoscopy in CRC screening. Objective: This study aimed to evaluate the cost-effectiveness of various CRC screening strategies, including no screening, fecal immunochemical test (FIT) positive result followed by a conventional colonoscopy, FIT positive result followed by AI-assisted colonoscopy, direct colonoscopy, and direct AI-assisted colonoscopy. Methods: This study modeled a hypothetical population based on current clinical practice in Asia, where CRC screening typically begins at the age of 50 years. The cost-effectiveness of various population-based CRC screening strategies, including AI-assisted colonoscopy, was evaluated by comparing incremental cost-effectiveness ratios (ICERs) and outcome measures such as cancer-related life years lost, number of CRC cases prevented, life years saved, and total cost per life year saved. Data from the international literature and the government gazette were accessed to calculate relevant cost and performance estimates. The data were entered into a decision analysis algorithm based on a Markov model. Results: Compared to no screening strategy, the ICERs of FIT+colonoscopy (FIT followed by conventional colonoscopy if the FIT result is positive), FIT+AI-assisted colonoscopy (FIT followed by AI-assisted colonoscopy if the FIT result is positive), colonoscopy alone, and AI-assisted colonoscopy were US $138,539, US $122,539, US $203,929, and US $180,444, respectively. When compared with FIT+colonoscopy, the FIT+AI-assisted colonoscopy strategy resulted in fewer cancer-related life years lost (5355 y vs 5327 y), a higher number and proportion of CRC cases prevented (120 vs 132 and 3.7% vs 4.1%), more life years saved (280 y vs 308 y), and lower total cost per life year saved (US $944,008 vs US $854,367). FIT+AI-assisted colonoscopy, which had the lowest ICER (US $122,539) dominated all other strategies, particularly compared to FIT+colonoscopy, with an ICER of –US $36,462. Among primary screening methods, AI-assisted colonoscopy dominated conventional colonoscopy (ICER –US $39,040). Conclusions: For an Asian population, FIT followed by AI-assisted colonoscopy represented the most cost-effective CRC screening strategy. It had the lowest ICER and the lowest additional cost among all 4 evaluated strategies.